Global Interleukin Inhibitors Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Type;

IL-17, IL-23, IL-1, IL-5, IL-6, and Others.

By Route Of Administration;

Subcutaneous (SC) and Intravenous (IV).

By Application;

Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease, and Others.

By End User;

Hospitals, Specialty Clinics, and Others.

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn460392799 Published Date: April, 2025 Updated Date: May, 2025

Introduction

Global Interleukin Inhibitors Market (USD Million), 2021 - 2031

In the year 2024, the Global Interleukin Inhibitors Market was valued at USD 17,071.77 million. The size of this market is expected to increase to USD 42,981.16 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 14.1%.


Global Interleukin Inhibitors Market Growth, Share, Size, Trends and Forecast

*Market size in USD million

CAGR 14.1 %


Study Period2025 - 2031
Base Year2024
CAGR (%)14.1 %
Market Size (2024)USD 17,071.77 Million
Market Size (2031)USD 42,981.16 Million
Market ConcentrationLow
Report Pages398
17,071.77
2024
42,981.16
2031

Major Players

  • Novartis AG
  • AbbVie Inc
  • Regeneron Pharmaceuticals
  • Johnson & Johnson Services
  • F. Hoffmann-La Roche Ltd
  • AstraZeneca
  • Bausch Health
  • GlaxoSmithKline

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Global Interleukin Inhibitors Market

Fragmented - Highly competitive market without dominant players


The interleukin inhibitors market is experiencing significant growth, fueled by the rising prevalence of autoimmune diseases and chronic inflammatory conditions. These inhibitors, which target specific cytokines involved in immune responses, are emerging as a key therapeutic option.

Advances in Pharmaceutical Research
Pharmaceutical innovation continues to propel the interleukin inhibitors market forward. Research into cytokine mechanisms has spurred the development of new drugs, with several major pharmaceutical companies investing heavily in creating next-generation interleukin inhibitors. Biologics, which account for more than 50% of the market, are at the forefront of this shift, offering targeted treatments with improved efficacy and fewer side effects. The focus on biologics and personalized medicine is expected to continue shaping the future of the industry.

Regulatory Approvals Fuel Market Growth
The accelerating rate of regulatory approvals for interleukin inhibitors is a key driver of market expansion. Agencies like the FDA and EMA have granted approvals for numerous interleukin inhibitors, further solidifying their place in mainstream medical practice. Over the past five years, the number of approved biologics has increased by approximately 15%, setting the stage for even greater market growth and a competitive landscape in the coming years.

Market Dynamics
Despite its positive outlook, the interleukin inhibitors market faces several challenges. High treatment costs and complex manufacturing processes remain significant hurdles. These factors could restrict access to therapies in certain regions, particularly in emerging markets. However, with ongoing advances in production techniques and the increasing availability of biosimilars, the cost of treatment is expected to become more manageable. Additionally, the growing trend toward personalized medicine will likely contribute to broader market adoption and mitigate some of these barriers.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Type
    2. Market Snapshot, By Route Of Administration
    3. Market Snapshot, By Application
    4. Market Snapshot, By End User
    5. Market Snapshot, By Region
  4. Global Interleukin Inhibitors Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Growing Demand for Targeted Therapies
        2. Advancements in Biotechnology
        3. Rising Healthcare Expenditure
        4. Expanding Applications in Autoimmune Disorders
      2. Restraints
        1. Adverse Effects and Safety Concerns
        2. Stringent Regulatory Requirements
        3. Competition from Biosimilars
        4. Limited Access in Developing Regions
      3. Opportunities
        1. Expansion into Emerging Markets
        2. Personalized Medicine Approaches
        3. Collaborations for Research and Development
        4. Increasing Awareness and Education
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Interleukin Inhibitors Market, By Type, 2021 - 2031 (USD Million)
      1. IL-17
      2. IL-23
      3. IL-1
      4. IL-5
      5. IL-6
      6. Others
    2. Global Interleukin Inhibitors Market, By Route Of Administration, 2021 - 2031 (USD Million)
      1. Subcutaneous (SC)
      2. Intravenous (IV)
    3. Global Interleukin Inhibitors Market, By Application, 2021 - 2031 (USD Million)
      1. Psoriasis
      2. Psoriatic Arthritis
      3. Rheumatoid Arthritis
      4. Asthma
      5. Inflammatory Bowel Disease
      6. Others
    4. Global Interleukin Inhibitors Market, By End User, 2021 - 2031 (USD Million)
      1. Hospitals
      2. Specialty Clinics
      3. Others
    5. Global Interleukin Inhibitors Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Novartis AG
      2. AbbVie Inc
      3. Regeneron Pharmaceuticals
      4. Johnson & Johnson Services
      5. F. Hoffmann-La Roche Ltd
      6. AstraZeneca
      7. Bausch Health
      8. GlaxoSmithKline
  7. Analyst Views
  8. Future Outlook of the Market